Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japanese pharma are responding to patent cliffs much like their Western counterparts, through lifecycle management, cost containment and increased focus on emerging markets. In Part 1 of PharmAsia News' roundup of the Japanese Q1 earnings season, Astellas and Eisai respond to patent loss of blockbuster products by highlighting product development milestones and patent extensions